Analysis of the subcellular location of lncRNA SLC16A1-AS1 and its interaction with premature miR-5088-5p in oral squamous cell carcinoma

A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs

“…Similarly, in patients with glioblastoma, SLC16A1-AS1 might promote cancer cell proliferation by regulating miR-149 methylation and could be considered a potential diagnostic marker in glioblastoma ( Long et al, 2021 ). Also, there were several studies about the function of SLC16A1-AS1 in oral squamous cell carcinoma ( Feng et al, 2020 ; Li et al, 2022 ), and triple-negative breast cancer ( Jiang et al, 2022 ). As for lung cancer, Liu et al (2020) have proved that the expression of SLC16A1-AS1 was significantly lower in NSCLC tissue than that in adjacent tissue, and SLC16A1-AS1 over-expression could block the cell cycle and promote cell apoptosis in vitro , suggesting that it might act as a potential biomarker for patients with NSCLC.…”

Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

“…SLC16A1 antisense RNA 1 (SLC16A1-AS1) is a novel antisense lncRNA which has become a rising star in oncological research. SLC16A1-AS1 exhibits aberrant expression in a variety of cancers, including glioblastoma (GBM) [ 93 , 94 ], oral squamous cell carcinoma (OSCC) [ 95 , 96 ], hepatocellular carcinoma (HCC) [ 97 – 100 ], renal cell carcinoma (RCC) [ 101 ], bladder cancer [ 102 ], cervical squamous cell carcinoma(CSCC) [ 103 ], breast cancer [ 104 – 106 ], osteosarcoma [ 107 ], and non-small cell lung cancer (NSCLC) [ 108 ]. Furthermore, SLC16A1-AS1 exhibits multiple biological roles in these primary malignancies, highlighting its complexity in tumorigenesis and its potential as a tumor biomarker [ 93 – 108 ].…”

“…SLC16A1-AS1 plays a nuanced role in the pathogenesis of OSCC. Li et al [ 95 ] delves into the interaction between SLC16A1-AS1 and miR-5088-5p (both mature and premature forms) in OSCC. This study indicates that SLC16A1-AS1 acts as a tumor suppressor by modulating the behavior of miR-5088-5p, which in turn affects cancer cell proliferation [ 95 ].…”

“…Li et al [ 95 ] delves into the interaction between SLC16A1-AS1 and miR-5088-5p (both mature and premature forms) in OSCC. This study indicates that SLC16A1-AS1 acts as a tumor suppressor by modulating the behavior of miR-5088-5p, which in turn affects cancer cell proliferation [ 95 ]. The specific mechanism through which SLC16A1-AS1 exerts this suppressive effect, particularly in relation to miR-5088-5p, highlights a complex interplay that could significantly influence OSCC progression.…”

“…Notably, Song et al [ 100 ] demonstrated that SLC16A1-AS1 shows high sensitivity and specificity in predicting both survival and the likelihood of distant metastasis in HCC patients. Conversely, in OSCC, SLC16A1-AS1 exhibits variable expression, being both upregulated and downregulated in different studies [ 95 , 96 ], with implications on histologic grades and overall survival. This variability underscores the intricate nature of SLC16A1-AS1’s role in cancer biology.…”